About Egetis

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Patents and trademarks

An active strategy

Egetis’ patents encompass products based on PLED compounds and associated treatment methods.

The company’s patent applications do not just cover the first products based on PLED compounds and the initial clinical application. They also cover a broad spectrum of other applications, such as production methods and formulations for Egetis’s products.

Egetis carefully monitors developments concerning its intellectual property rights in all relevant areas as well as competing technologies and companies. Egetis’ patent strategy for intellectual property rights has been developed in close, long-term cooperation with its external US patent attorney.

Egetis has had trademark protection for the trademark PledOx® since 2010, for Aladote® since 2015 and for Emcitate® since 2017.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com